S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

ESPR Esperion Therapeutics Inc

1.90

-0.09 (-4.52%)

27 Apr 2024 - Closed

Delayed by 15 minutes

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

null

Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Mar 2024 to Apr 2024

Click Here for more Esperion Therapeutics Charts.

Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Apr 2023 to Apr 2024

Click Here for more Esperion Therapeutics Charts.

Esperion Therapeutics Inc News

Esperion to Report First Quarter 2024 Financial Results on May 7
Tuesday 23 April 2024 (4 days ago) • GlobeNewswire Inc.

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
Monday 8 April 2024 (3 weeks ago) • GlobeNewswire Inc.

Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
Monday 1 April 2024 (4 weeks ago) • GlobeNewswire Inc.

Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
Tuesday 26 March 2024 (1 month ago) • GlobeNewswire Inc.

Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
Tuesday 26 March 2024 (1 month ago) • GlobeNewswire Inc.

U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
Saturday 23 March 2024 (1 month ago) • Business Wire

U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
Saturday 23 March 2024 (1 month ago) • GlobeNewswire Inc.

CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events
Saturday 23 March 2024 (1 month ago) • GlobeNewswire Inc.

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Wednesday 28 February 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Tuesday 27 February 2024 (2 months ago) • Edgar (US Regulatory)

Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
Tuesday 27 February 2024 (2 months ago) • GlobeNewswire Inc.

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Saturday 17 February 2024 (2 months ago) • GlobeNewswire Inc.

More Esperion Therapeutics Inc News Articles

Gold vs US Dollar

AUD vs US Dollar

National Australia Bank

Australia And New Zealan...

Verizon Communications

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions